Hyatt Embarcadero Hotel, San Francisco - Feb 25-26, 2010

The 2010 Epilepsy Pipeline Update Conference continues our tradition of showcasing new and promising treatments, with epilepsy as a portal into the broad CNS market. This in-depth meeting will focus on preclinical, early- and late-stage clinical development strategies, and investment and business development opportunities.

Sponsored by Epilepsy Therapy Project, a 501-c-3 non-profit organization, is a recognized leader in accelerating new therapies for people with epilepsy. Our role is to provide the most current information on promising new therapies, and to be the matchmaker between scientists, entrepreneurs, investors and licensees of all types.

Why Attend the Epilepsy Pipeline Conference?

This in-depth meeting showcases emerging CNS companies and scientific entrepreneurs alongside established companies presenting their strategies, candidates and development programs to potential venture capital, public investors and partners. New anti-epilepsy products, in particular, are known to provide the optimal pathway for CNS therapeutic development with well-characterized mechanisms, therapeutic approaches, functional models and well-defined clinical endpoints for regulatory studies.

Thoughtfully selected by Epilepsy Therapy Project’s expert Scientific and Business Advisory Boards (http://www.epilepsy.com/epilepsy_therapy_project), presenters will cover the most innovative and intriguing therapeutic targets and programs in development today for epilepsy - with potential for broader CNS applications. Hear insights from scientific, clinical and industry leaders relevant to investment in epilepsy and broader CNS areas. Recent advances, creating remarkable investment and commercial opportunities, require expert perspective on risk profile, clinical advantages and product lifecycle management.

We hope you will join us for this enriched 1 ½ day opportunity:

• The latest pipeline developments
• Pre-clinical evaluation of new molecular entities
• Predictive stimulation and combination drug-device approaches
• Phase 2 readouts and Phase 3 clinical trials design
• Regulatory and pricing perspective and more...

Who Should Attend?

Business development, industry and investors focusing on epilepsy and CNS opportunities, and staying current on the latest treatment and pipeline advances.

Sponsorship and Speaking Opportunities:

Please contact: Joyce Cramer, President joyce@epilepsytherapyproject.org to discuss featuring your company at this key CNS conference.

Registration

The conference venue has limited seating. Registration will be limited to the space available. Early pre-registration is encouraged.

Register online here.

Open or download the Registration Form here. (PDF)

Submit by email attachment to conference@epilepsytherapyproject.org or by fax to 480-247-9490.

Complimentary Investor/BD Registration Available:

Please contact: Joyce Cramer, President, Epilepsy Therapy Project, joyce@epilepsytherapyproject.org for additional information about the conference or complimentary registration for investors, business development and licensing executives.

Special Room Reservation Rate

Hyatt Regency San Francisco
Five Embarcadero Center
San Francisco, CA 94111

The group rate for a King or Double Room is $195/night. Call the Passkey phone number, 1-888-421-1442 or go to https://resweb.passkey.com/go/EPSI to make a reservation online.